CHA Vaccine Research Institute (KOSDAQ:261780)

Market Cap	86.10B +12.4%
Revenue (ttm)	158.62M -57.2%
Net Income	-14.25B
EPS	-531.06
Shares Out	26.87M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,174,733
Average Volume	182,571
Open	2,960.00
Previous Close	2,960.00
Day's Range	2,950.00 - 3,290.00
52-Week Range	2,360.00 - 3,660.00
Beta	0.58
RSI	69.57
Earnings Date	n/a

About KOSDAQ:261780

Cha Vaccine Research Institute Co., Ltd., a research-oriented biotechnology company, researches and develops a range of vaccine products for infectious and chronic diseases. Its product pipeline includes HBV vaccine that is in Phase IIb planning for the prevention of hepatitis B; Adjuvanted HBV vaccine that is in Phase I/IIa for the treatment of chronic hepatitis B; and VZV Vaccine, which is in pre-clinical planning stage for the prevention of Herpes Zoster. The company also develops influenza vaccine, recombinant MBL, TB vaccine, and cancer va...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2000
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 261780

Financial Performance

In 2024, KOSDAQ:261780's revenue was 370.66 million, an increase of 26.02% compared to the previous year's 294.12 million. Losses were -10.14 billion, 479.5% more than in 2023.